MR angiography with a new rapid‐clearance blood pool agent: Initial experience in rabbits

Abstract

The purpose of this study was to assess a new Gd‐based macromolecular intravascular contrast agent (P792, Vistarem®; Laboratoire Guerbet, Aulnay sous Bois, France) for MR angiography (MRA). P792 is a macrocyclic gadolinium compound based on a gadoterate meglumine structure substituted by hydrophilic arms. In vitro imaging of phantoms containing varying concentrations of P792 and gadoterate meglumine (Gd‐DOTA) was performed. In rabbits (N = 5), arterial concentrations for P792 and Gd‐DOTA were determined, and in vivo 3D MRA was performed. For gadolinium concentrations ranging from 200 to 3000 μmol/l, in vitro imaging showed higher SNR values for P792 compared to Gd‐DOTA. Determination of arterial Gd concentration showed comparable bolus phase curves for P792 and Gd‐DOTA. With P792, higher concentrations were obtained due to a restricted diffusion into the interstitial space. P792 allowed acquisition of high‐quality MR angiograms. Image quality was rated as superior for P792 in the post‐bolus phase images. In conclusion, P792 appears to be well suited for high‐quality first‐pass and equilibrium‐phase MRA. The intravascular properties lead to an excellent signal in the vasculature, with limited background enhancement. Since the agent is rapidly renally excreted, it should be well suited for perfusion and permeability imaging. Magn Reson Med 48:844–851, 2002.